UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 19, 2012

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33038 (Commission File Number)

(State or Other Jurisdiction of Incorporation)

1180 Avenue of the Americas 20th Floor New York, NY (Address of Principal Executive Offices) **84-1475672** (IRS Employer Identification No.)

> **10036** (Zip Code)

(646) 214-0700

(Registrant's telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events

ZIOPHARM Oncology, Inc., or the Company, will present the attached discussion of the Company's palifosfamide development strategy and milestones, as well as the Company's IL-12 DNA therapeutics program, at the Company's Research and Development Day in New York, New York, being held on June 19, 2012.

A copy of the above referenced presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01	Financial Statements and Exhibits	
(d)	Exhibits	
	Exhibit No.	Description
	99.1	Presentation of the Company dated June 19, 2012

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

Date: June 19, 2012

By: /s/ Caesar Belbel Name: Caesar Belbel Title: Executive Vice President, Chief Legal Officer and Secretary

INDEX OF EXHIBITS

Exhibit No.	Description
99.1	Presentation of the Company dated June 19, 2012
	4

Exhibit 99.1



ZIOPHARM Oncology

2012 Research & Development Day June 19, 2012

Jonathan Lewis, MD, PhD Chief Executive Officer

www.ziopharm.com


Forward-Looking Statements

This presentation contains certain forward-looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether any of our therapeutic candidates will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic candidates will be successfully marketed if approved; whether our DNA-based biotherapeutics discovery and development efforts will be successful; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from pharmaceutical and biotechnology companies; the development of and our ability to take advantage of the market for DNA-based biotherapeutics; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim reports filed with the SEC including, but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our Quarterly Report on Form 10-Q for the fiscal guarter ended March 31, 2012. Our audience is cautioned not to place undue reliance on these forwardlooking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or nonoccurrence of any events.

ZIOPHARM Oncology

www.ziopharm.com

Data-Driven Oncology Portfolio



Many Thanks

Our Guests

- Wael Harb, MD, Chief Community Officer of the Hoosier Oncology Group, Director of Cancer Services and Clinical Research at Indiana University Health Arnett
- Ramaswamy Govindan, MD, Head of the Thoracic Oncology Program, Co-Director of Medical Oncology, and Professor of Medicine, Oncology Division at Washington University School of Medicine
- Robert Maki, MD, PhD, Chief of the Pediatric Hematology/Oncology Division, Medical Director of the Sarcoma Cancer Program, Tisch Cancer Institute at Mount Sinai Medical Center
- Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, Medical Director, Breast Cancer Programs

From ZIOPHARM

- Hagop Youssoufian, MSc, MD, President of Research and Development and Chief Medical Officer
- Mark Thornton, MD, PhD, Executive Vice President, Government Affairs, Health Policy and Advocacy and Chief Quality Compliance Officer

ZIOPHARM Oncology

www.ziopharm.com

Program

<u>Palifosfamide</u>		
Small Cell Lung Cancer		Rational Design and Preclinical Activity
5		Phase 1 Bridging Study in SCLC
	i te	MATISSE: A Phase 3 Study
Sarcoma	-	FDA, PFS & the Shifting Landscape in Sarcoma
	-	The PICASSO 3 Study
DNA Therapeutics	3 <u>11</u>	AD-IL12 and DNA Therapeutics
Rational Drug Development	222	Cancer Biology in the 21st Century:
Kuttonut Drug Development		Translation in the Clinic

S ZIOPHARM Oncology


www.ziopharm.com




ZIOPHARM Oncology

www.ziopharm.com

Biosynthesis & Metabolism



Palifosfamide Safety ~ Bypass Drug Resistance ~ Target Stem Cells




Struck RF et al. Cancer Chemother Pharmacol (2000) 45: 59-62

ZIOPHARM Oncology

www.ziopharm.com

Rational Drug Development: Extensive Early Clinical Study Informed Late-Stage Programs



Wael Harb, MD


Small Cell Lung Cancer

Rational Design and Preclinical Activity Phase 1 Bridging Study

ZIOPHARM Oncology

www.ziopharm.com

A Novel DNA-Targeted Drug



Low Toxicity	No neurotoxicity or bladder toxicity
Minimal Patient-to Patient Variability	On/off rapid kinetics minimize interpatient variability; target cancer
Broad Activity	Active in multiple tumor cell lines and human cancer xenografts, including sarcoma
Activity in Resistant Tumors	Bypasses several known mechanisms of drug resistance Active in ifosfamide- and cyclophosphamide-resistant tumor cell lines and xenografts
Activity in ALDH (Cancer Stem Cells)	Active in ALDH3A1-overexpressing xenografts

C ZIOPHARM Oncology

www.ziopharm.com

ALDH is a validated marker of cancer stem cells

ALDH+ cells are generally resistant to treatment and chemotherapy

ALDH+ cells are readily detectable in multiple subtypes of epithelial cancer, bone marrow derived cancer and sarcoma

 ${\bf SCLC}$ direct patient xenografts have an abundant population of tumor cells that are ASCL1+/CD133+/ALDH1+

Hingorani P et al. Cancer Chemother Pharmacol (2009) 64: 733-40 Jiang T et al. Cancer Res (2009) 69: 845-54 Minna J. 12th Annual Targeted Therapies of Lung Cancer Meeting (2012), IASLC, Santa Monica

ZIOPHARM Oncology

www.ziopharm.com

IPM1002: Phase 1 Palifosfamide + Doxorubicin – Early Activity in STS and SCLC

- 13 subjects with advanced/refractory cancers, 12 evaluable
 8 STS, 2 SCLC
- Study identified a clinically tolerable and effective dose combination
 - Doxorubicin (75 mg/m²), palifosfamide-tris (150 mg/m²)
 - C_{max} and AUC comparable to efficacious levels in mouse models
 - Grade 3/4 AEs: Hematologic
 - <u>No</u> encephalopathy, hemorrhagic cystitis, renal dysfunction
- 3 PRs: Sarcoma (2), SCLC (1)

www.ziopharm.com

IPM1004: Phase 1b Interim Data Palifosfamide with Carboplatin/Etoposide (PaCE) Presented at AACR NCI EORTC

- Dose escalation palifosfamide and etoposide in selected cancers
 - SCLC
 - Other (germ cell; ovarian; uterine leiomyosarcoma; NSCLC)
- 15 patients reported at interim
 - SCLC, 5 (all previously treated in first-line setting; then progressing)
 - NSCLC,2
 - Ovarian, 2
 - Germ Cell Tumor, 1
- SAEs in 6 patients
 - Including thrombocytopenia (4), leukopenia (2), neutropenia (2)
 - DLT = neutropenic fever
- MTD of palifosfamide = 130 mg/m^2 (with E 90 mg/m² and C AUC4)
- New dose cohort with E 100 mg/m² subsequently activated


Harb et. al. AACR NCI EORTC 2012.

ZIOPHARM Oncology

www.ziopharm.com

Rapid Clinical Activity: Primary Mediastinal Nonseminomatous Germ Cell Tumor

- Normalization of tumor markers:
 - Previously treated (including ifosfamide containing regimen developed encephalopathy)
 - $-~\beta$ HCG reduction: 2358 to 12 mU/Ml
 - Completed 4 cycles of therapy



ZIOPHARM Oncology

www.ziopharm.com

Tumor Response

Response Assessment ¹	Patients N=18	Cancer Types
PR	6	Germ Cell Tumor, NSCLC, Ovarian, SCLC (2), Uterine Leiomyosarcoma
SD	7	Ovarian (2), NSCLC, SCLC (2), Squamous Cell, DFSP
PD	5	Adenocarcinoma, Carcinoid, Pancreatic, SCLC (2)

¹ Response Assessment per RECIST 1.1 definitions and/or assessed per Biomarkers.

Clinical Benefit Rate = 67% Range of cycles 2 – 17+

ZIOPHARM Oncology

www.ziopharm.com

Ramaswamy Govindan, MD

MATISSE: A Phase 3 Study in Extensive-Stage Small Cell Lung Cancer

ZIOPHARM Oncology

www.ziopharm.com

- Significant unmet medical need in cancer with no new front-line therapies in decades
 - Approximately 15% of lung cancers
 - 30,000-35,000 U.S. incidence/200,000 worldwide¹ (China annual incidence alone growing to >150,000²)
- Platinum plus etoposide SOC front-line; concurrent w/radiation in limited stage; only topotecan approved second-line

¹ SEER, Globocon.

²Derived from; Liu et. al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ. 1998;317:1411.

ZIOPHARM Oncology

www.ziopharm.com

Contemporary Phase 3 Trials in 1st Line ES-SCLC: Ifosfamide – Only Positive Study

Study	Regimen	Results
Irinotecan		
Lara PN etal. J Clin Oncol 2009;27:2530	Cisplatin + etoposide vs cisplatin + IRINOTECAN	No difference in PFS or OS
Topotecan		
Eckardt JR et al. J Clin Oncol 2006;24:2044	TOPOTECAN + cisplatin vs cisplatin + etoposide	No difference in RR or OS
Bevacizumab		
Intergroupe Francophone de Cancerologie Thoracique	Chemotherapy (including cisplatin + etoposide) ± BEVACIZUMAB	Suspended
Paclitaxel		
Niell HB et al. J Clin Oncol 2005;23:3752	Cisplatin + etoposide ± PACLITAXEL	No difference in OS; tx-related mortality higher w/paclitaxel
Pemetrexed		
Socinski MA et al. J Clin Oncol 2009;27:4787	PEMETREXED + carboplatin vs carboplatin + etoposide	No difference in PFS or OS
Ifosfamide		
Loehrer PJ et al. J Clin Oncol 1995;13:2594. (Hoosier Oncology Group)	Cisplatin + etoposide ± IFOSFAMIDE	Significant survival advantage for ifosfamide

210PHARM Oncology

www.ziopharm.com

Efficacy Rationale: Positive Phase 3 Randomized Ifosfamide Study in SCLC

Cisplatin plus etoposide <u>with or without ifosfamide</u> in extensive-stage <u>small-cell lung cancer</u>: Hoosier Oncology Group - <u>Einhorn et. al.</u>

VIP regimen:

etoposide (75 mg/m²), ifosfamide (1.2 g/m²), cisplatin (20 mg/m²) - days 1 to 4 x four cycles.

- Statistically significant difference in <u>median survival</u> 7.3 months vs 9.0 months (P=.045)
- 2-year survival 5% vs 13%
- Difference in time to progression statistically different (P = .039)
- Excess toxicity: grade 3/4 myelotoxicity, neurotoxicity, pneumonitis
- In-patient therapy, inconvenience despite efficacy, <u>NEVER</u> pursued as Rx

ZIOPHARM Oncology

www.ziopharm.com

The MATISSE Study: Multicenter Adaptive Trial Investigating Small Cell Lung Cancer Survival Endpoints

 A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide, a Novel DNA Cross-linker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Patients with Extensive-Stage Small Cell Lung Cancer who have not received initial chemotherapy



ZIOPHARM Oncology

www.ziopharm.com



Design	Multinational, multi-center, randomized controlled, open- label, adaptive trial
N	Up to 548 subjects
Population	Males and females, age ≥18 years, with extensive-stage small cell lung cancer
Primary Endpoint	Overall survival (OS)
Secondary Endpoints	Progression-free survival (PFS) Objective response rate (ORR) Quality of Life (QOL) Disease related symptoms

C ZIOPHARM Oncology

www.ziopharm.com

Adaptive Clinical Trial Design:

- Prospectively planned opportunity to modify the study by adjusting specified aspects of the study design and/or hypotheses
- Adjustments based on analysis of real time data (usually interim data) from subjects in the study
- Analyses of accumulating study data performed at prospectively planned time points clearly defined in the study protocol
- Can occur with or without formal statistical hypothesis testing

Conventional Trial Design:


- Fixed sample size
- Does not have any adaptive elements or characteristics

ZIOPHARM Oncology

www.ziopharm.com


MATISSE Adaptive Trial Design





Palifosfamide: Rational Development in High Unmet Medical Need

- Rationale:
 - Ifosfamide has been <u>only front-line therapy to show survival</u> <u>benefit</u> added to SOC... but with *excessive toxicity*, never adopted
 - High mutant variability in SCLC necessitates a treatment with broad DNA, multi-genomic, cancer stem cell activity
 - Palifosfamide added to SOC demonstrating activity in refractory, progressing patients... combination well tolerated



www.ziopharm.com

Mark Thornton, MD, PhD

Sarcoma

FDA, PFS & the Shifting Landscape

ZIOPHARM Oncology

www.ziopharm.com

The Changing Landscape of PFS as a Primary Endpoint

- A PFS primary endpoint in Phase 3 registration trials has undergone pendulum swings over time, and is now in favor:
 - In 2011, four products were approved based on PFS as primary trial endpoint
 - In 2012, pazopanib (Votrient[®]) became the 5th precedent, and the first for STS
- Rajeshwari Sridhara, PhD, Deputy Director, DBV, at FDA in 2012:

PFS is considered clinical benefit in certain circumstances, and therefore meets requirement to grant <u>full approval</u> under FDA flexibility standards and practices

ZIOPHARM Oncology

www.ziopharm.com

"PFS as Primary Endpoint Is Here to Stay" Criteria for Full Approval Based on PFS

- Criteria for PFS (Sridhara, May 18, 2012):
 - Rare cancer
 - Large magnitude of benefit ("months not weeks")
 - High quality data
 - No negative impact/trend on OS
 - Favorable risk/benefit
- Note that setting (1st line, 2nd line) is not a factor in applying the policy. Rare is rare.
 - However, for a lead indication, sufficient numbers in safety database will be necessary

ZIOPHARM Oncology

www.ziopharm.com

Impact of Rare Disease Advocates on PDUFA

- PDUFA reauthorization cycle coincides with intensive reform lobbying by advocacy community
 - PDUFA will mandate FDA:
 - · Listen to patient input regarding acceptable risk/benefit
 - · Show evidence of flexibility in rare disease settings
 - Enhance use of accelerated approval beyond HIV/oncology
- Relevance to PFS
 - FDA's OHOP is leading the way on demonstrating increased flexibility on endpoints for rare cancers
 - Full approval of pazopanib for STS is type of evidence of flexibility that Congress is looking for
 - United sarcoma patient community showing FDA support

ZIOPHARM Oncology

www.ziopharm.com

Relevance to Regulatory Strategy for Palifosfamide in STS

- Current policy is clear by both precedent, as well as by recent public comments from senior FDA officials
- Pazopanib full approval for STS confirms sound strategy of PFS as primary endpoint for palifosfamide to attain FDA approval as lead indication in front-line STS
- PFS is appropriate primary endpoint for STS (rare cancer)
- Encouraging data to date (safety/efficacy), as well as favorable regulatory landscape, indicates palifosfamide optimized to meet other key criteria of PFS-based approval

www.ziopharm.com

Robert Maki, MD, PhD

The PICASSO 3 Study

ZIOPHARM Oncology

www.ziopharm.com

- Currently over 100,000 people diagnosed with STS worldwide; estimated metastatic front-line of 23,000 people for U.S. and Europe*
 - Estimated 9,000 treated for front-line metastatic disease in U.S., target indication
 - Estimated 14,000 being treated in Europe
- Doxorubicin alone, doxorubicin-based therapy currently SOC in front-line setting; NCCN recommends clinical trial participation whenever possible
- March 2012 ODAC; April 2012 FDA <u>full approval</u> of Votrient[®] validate PFS endpoint; May 2012 positive opinion from European CHMP

* Source: U.S.: IntrinsiQ Data, © Copyright 2012, IntrinsiQ, LLC an AmerisourceBergen Specialty Group company. All rights reserved; remainder of world Company estimated from epidemiology (SEER, NCCN).

ZIOPHARM Oncology

www.ziopharm.com

IPM2001: Phase 1/2 (Palifosfamide Monotherapy) Effect on Tumor Mass

Refractory Liposarcoma

Baseline





13.9 x 11.2 cm




9.0 x 7.0 cm

Presented at the Liddy Schriver Sarcoma Initiative, 2009

2 ZIOPHARM Oncology

www.ziopharm.com





Palifosfamide-tris by IV infusion over approximately 30 minutes. Doxorubicin by IV infusion over approximately 5 to 30 minutes.

ZIOPHARM Oncology

www.ziopharm.com

Multicenter, Randomized, Stratified, Balanced Phase 2 Data (PICASSO)

	Arm A: Pali+Dox	Arm B: Dox	
PFS: median	7.8 mos.	4.4 mos.	
PFS: hazard ratio	0.4	3	
OS: hazard ratio (<i>with crossover</i>)	0.7	8	
2-yr survival (<i>with crossover</i>)**	40%	30%	
Safety	 Similarity between arms <u>No</u> encephalopathy, hemorrhagic cystitis, Fanconi's Syndrome 		
Grade 3+ events	• Neutropenia and elevated creatinine (similar between arms)		

Phase 3: Correctly Modeled and Powered for PFS & OS

Source: Best of ASCO 2010 (PFS Data), internal analysis (OS Data) ** Expected 2-yr survival is 25% based on evaluation of randomized data

ZIOPHARM Oncology

www.ziopharm.com



Design Based on Successful Randomized Phase 2 Study with Similar Design


N:	Approximately 424 patients; front-line metastatic STS	
Regimen:	Palifosfamide + doxorubicin vs doxorubicin + placebo	
Primary Endpoint:	PFS for accelerated approval; OS for full approval Powered for PFS & OS	
PFS Power:	85% power to detect 0.60 HR, 3 month median Δ (p=0.0005, one-tailed)	
PFS Analysis:	Evaluation of PFS by IDMC following a pre-determined number of PFS events	
Study sites:	> 150 centers worldwide	
Results:	Pivotal PFS data expected 2H 2012	

ZIOPHARM Oncology

www.ziopharm.com

PICASSO 3 Study Schema






C ZIOPHARM Oncology

www.ziopharm.com

Palifosfamide for Front-Line Soft Tissue Sarcoma

- High unmet medical need with no new approved treatments in over 30 years in the front-line setting
- April 2012 FDA full approval of Votrient® validate PFS endpoint
- Objective of palifosfamide in combination with doxorubicin as standard of care for front-line metastatic STS
- · PICASSO 3 results highly anticipated



www.ziopharm.com



- A revolutionary technology for the precise, controlled delivery of therapeutic proteins *in vivo*
- Lead therapeutic / early validation of the platform
 - IL-12 is a prime target for a controlled release approach
 - IL-12 is an increasingly compelling target to big pharma
- "Next-wave" of therapeutic approaches in the research pipeline (antibody technology, protein-protein decoys, immunotoxins, etc.)
- Focused, disciplined approach to development will minimize expense while driving value through near-term proof-of-concept studies

ZIOPHARM Oncology

www.ziopharm.com

Hagop Youssoufian, MD

AD-IL12 and DNA Therapeutics


ZIOPHARM Oncology

www.ziopharm.com

Leverage the power of DNA technology to build novel therapeutic products

- **Precision:** control over biologic drug distribution (local/systemic)
- **Controlled:** in vivo control of dosing through first in-human biological on/off switch (RheoSwitch Therapeutic System[®])
- *Adaptable:* multiple therapeutic protein approaches

www.ziopharm.com




Using Natural Cell Biology to Produce Proteins

IL-12 DNA

- IL12
 - A renewed interest in an well characterized, naturally occurring cytokine
 - Activity alone and in combination
- Indications of interest
 - Melanoma
 - Breast cancer
 - Head and neck cancer



www.ziopharm.com




Two Clinical Stage Product Candidates

- DC-IL12 Phase 1b in metastatic melanoma
 - Safety profile predictable
 - 2 PRs, 2 SDs, biomarker effects

Ad-IL12 Phase 1b in metastatic melanoma

- Safe to date
- Preliminary activity
- Significant data expected 2H 2012



Pre-treatment

Post-treatment



Baseline

Necrosis prior to cycle 2

ZIOPHARM Oncology

www.ziopharm.com

Next Phase of Development:

- Remains a *significant unmet need* in metastatic melanoma despite evolving landscape
- Phase 2 to begin at confirmation of biologically effective dose
- Phase 2 modifications to include additional patient-selection criteria to maximize signal detection
- Planned to be completed 1H 2013

www.ziopharm.com


Additional Clinical and Preclinical Directions: Breast Cancer

- Significant unmet medical need
- Potential for multiple approaches to treatment:
 - Ad-IL12 monotherapy
 - Ad-IL12 in combination with palifosfamide (novel-novel strategy)
- Study design under evaluation

www.ziopharm.com

Additional Clinical and Preclinical Directions: Head and Neck Cancer + Erbitux[®]

- Head and neck cancer
 - Significant unmet medical need
 - Ad-IL12 in combination with Erbitux[®]
 - May lead to a pivotal study
 - Various paths forward



www.ziopharm.com

- IL12-based intratumoral therapy has yielded initial proof-of-concept and appears to be well tolerated
- Melanoma to be pursued as lead indication
 - Protocol discussions with FDA to establish and maintain alignment and clarity toward an approval path
- · Head-and-neck and breast cancer opportunities being considered



www.ziopharm.com


Larry Norton, MD

Cancer Biology in the 21st Century: Translation in the Clinic


ZIOPHARM Oncology

www.ziopharm.com


Tycho Brahe 1546-1601 -




Johannes Kepler 1571-1630 -



Metastatic Cell Lines Grow Faster in the Primary Site But Ki67 (Mitotic Fraction) is Not Greater than in Non-Metastatic Lines




Minn, Gupta et al., Nature 2005



Norton, Massagué: Nature Med 2006

Self-Seeding Explains Gompertzian Growth

Smaller Tumor = Greater Surface to Volume Ratio = Faster Growth at Surface Bigger Tumor = Lower Surface to Volume Ratio = Slower Growth at Surface Growth from Outside \rightarrow In Creates a Stellate Pattern



 $dN_t/dt = k^*N_t^{a/c} - N_t^{b/c}$




Figure 1 Palifosfamide I.V. vs. MX-1 Breast Cancer Xenograft


Jonathan Lewis, MD, PhD

In Conclusion...

ZIOPHARM Oncology

www.ziopharm.com

Data-Driven Oncology Portfolio



Two Pivotal Programs Representing Significant, Global Market Potential





>\$1 Bn total market potential

	STS Patients Treated	Blended EU/US Price Per Patient		er Patient
		\$ 30,000	\$ 40,000	\$ 50,000
	9,000	\$ 270	\$ 360	\$ 450
Soft Tissue Sarcoma	10,000	\$ 300	\$ 400	\$ 500
	11,000	\$ 330	\$ 440	\$ 550
	14,000	\$ 420	\$ 560	\$ 700
Small Cell Lung Cancer	16,000	\$ 480	\$ 640	\$ 800
	18,000	\$ 540	\$ 720	\$ 900

Asia/Latin America Opportunity: +\$600 – \$900 M

* Source: Based on Company projections.

ZIOPHARM Oncology

www.ziopharm.com

(sales in millions)

June 19, 2012

Palifosfamide and DNA Therapeutics: 2012 Anticipated Key Clinical Milestones


Palifosfamide	DNA Therapeutics		
PICASSO 3 STS Pivotal PFS Data 2H 2012	IL-12 DNA Program Phase 1 Data 2012		
MATISSE SCLC Phase 3 Initiation 2Q 2012	Phase 2 Melanoma 2H 2012		
	New DNA Candidates Preclinical Data 2012 		

CIOPHARM Oncology

www.ziopharm.com

Balance Sheet Support Through Key Milestones

- Primary shares outstanding: approximately 79.5MM
- Cash: approximately \$128MM @ 3/31/12



www.ziopharm.com

An intelligent portfolio of therapeutics addressing unmet medical needs in cancer

- Palifosfamide
 - Wholly-owned asset
 - Near-term, Phase 3 study results in STS
 - Phase 3 for SCLC now enrolling
 - Potential in multiple solid and hematological tumors
 - >\$1 Bn total market potential in two indications alone
- DNA therapeutics targeting established treatment pathway into Phase 2 study
 - Exploring multiple avenues for revolutionary treatment modality
- Balance sheet support through multiple key milestones

ZIOPHARM Oncology

www.ziopharm.com



ZIOPHARM Oncology

Better Cancer Medicine

Questions

www.ziopharm.com